Brett R Hagen has sold ALVR and made no open-market buys since Feb 2021

Hagen Brett R (Brett R. Hagen) is a corporate insider and senior finance executive serving as Chief Accounting Officer at AlloVir, Inc. (NASDAQ: ALVR), where he oversees public company financial reporting, accounting operations, and compliance, and has recently executed multiple Form 4 transactions in AlloVir stock in his capacity as an officer and insider.( In parallel, he serves as Chief Accounting Officer and principal financial officer at Kalaris Therapeutics, Inc., having held the Chief Accounting Officer role since January 2019 and being designated principal financial officer following the resignation of the company’s CFO in April 2026.( Hagen is recognized as a senior financial biotech executive with extensive SEC reporting, SOX controls, treasury, and FP&A experience, and has been described as an energetic, collaborative leader in fast‑paced public company environments.(

Over his career, Hagen has held a series of senior finance and accounting roles in life sciences and financial services companies, including senior director of finance and accounting at Eloxx Pharmaceuticals, vice president of finance and controller at Proteostasis Therapeutics, controller positions at BIND Therapeutics and BioProcessors, and vice president of finance at Boston Private Financial Holdings.( He previously served as Chief Accounting Officer and vice president of finance at Proteostasis Therapeutics and has accumulated insider trading records across multiple issuers, including AlloVir, Kalaris Therapeutics, Proteostasis Therapeutics, and Yumanity Therapeutics.( Hagen holds a B.A. from the University of Minnesota, a graduate degree in accounting from Wright State University (MAcc), and a graduate degree in finance from Suffolk University, reflecting a combined academic background in accounting and finance that underpins his leadership in public company finance functions.(

Written by Perplexity from public sources.